Reproductive health of men in families with hereditary breast and ovarian cancer syndrome

Cover Page

Cite item

Abstract

hereditary breast and ovarian cancer syndrome is a hereditary condition. The cause of this syndrome are mutations in the BRCA1/2 genes. The frequency of these mutations is the same in men and women. The purpose of this study: to assess the reproductive health of men in families with hereditary breast and ovarian cancer syndrome. The study included first-degree relatives of 172 patients with verified ovarian cancer stages I–II. Methods. Identification of mutations in the BRCA 1/2 genes was carried out by the molecular genetic analysis complex "Oncogenetics BRCA" (OOO NPF "Litech", Moscow, Russia). Results. The distribution of BRCA1/2 mutations approximately corresponds to autosomal dominant inheritance. Among the sons and brothers of carriers of BRCA1/2 mutations, 97 carriers and 115 non-carriers were identified. In male relatives of BRCA1/2 mutation carriers, BRCA1 mutations predominate, accounting for 78% of all detected mutations, with the 185delAG mutation accounting for 35.05% of all registered mutations. Carriers of the 185delAG and 6174deIT mutations have high testosterone levels. With the 5382insC, Cys61Gly and 185delAG mutations, the luteinizing hormone level is low. Carriers of the 185delAG mutation have low luteinizing hormone levels, and in carriers of the 5382insC and Cys61Gly mutations, low luteinizing hormone levels are accompanied by low testosterone levels. In males carrying BRCA1\2 mutations, changes in spermatogenesis are observed, including azoospermia – with mutations 5382insC and 6174deIT, a high level of sperm agglutination is observed. The data obtained allow us to expand our understanding of the genetic regulation of spermatogenesis.

About the authors

M. V Boskhomdzhieva

Republican Oncology Dispensary named after E.S. Timoshkaeva, Elista

Email: miravladimirovna1450@gmail.com

A. A Nikolaev

Astrakhan State Medical University of the Ministry of Health of the Russian Federation

Email: chimnik@mail.ru

M. V Ploskonos

Astrakhan State Medical University of the Ministry of Health of the Russian Federation

Email: chimnik@mail.ru

References

  1. Hall J.M., Lee M.K., Newman B., Morrow J.E., Anderson L.A., Huey B. Linkage of early-onset familial breast cancer to chromosome 17q21 // Science. 1990. Vol. 250. № 6. P. 1684 – 1689. doi: 10.1126/science.2270482
  2. Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 // Science. 1994. Vol. 266. P. 66 – 71. doi: 10.1126/science.7545954
  3. Li Q., Engebrecht J. BRCA1 and BRCA2 Tumor Suppressor Function in Meiosis // Frontiers in Cell and Developmental Biology. 2021. Vol. 23. № 9. P. 668309 – 668325 doi: 10.3389/fcell.2021.668309
  4. Fraile-Bethencourt E., Valenzuela-Palomo A., D?ez-G?mez B., Goina E., Acedo A., Buratti E., Velasco E.A. Mis-splicing in breast cancer: identification of pathogenic BRCA2 variants by systematic minigene assays // The Journal of Pathology. 2019. Vol. 248. № 4. P. 409 – 420. doi: 10.1002/path.5268.
  5. Yoshida R. Hereditary breast and ovarian cancer (HBOC): Review of its molecular characteristics, screening, treatment, and prognosis // Breast Cancer. 2020. Vol. 28. № 5. P. 1167 – 1180. doi: 10.1007/s12282-020-01148-2
  6. Mikwar M., MacFarlane A.J., Marchetti F. Mechanisms of oocyte aneuploidy associated with advanced maternal age. // Reviews in Mutation Research. –2020. –vol.785. – P. 108320. doi: 10.1016/j.mrrev.2020.108320.
  7. Коган М.И., Чибичан М.Б., Водолажский Д.И. Экспрессия генетических локусов в мононуклеарной фракции периферической крови больных раком предстательной железы // Онкоурология. 2012. № 1. С. 40 – 48.
  8. WHO laboratory manual for the examination and processing of human semen. 6th ed. Geneva: WHO Press. 2021. 276 p. DOI.org/10.5534/wjmh.210074
  9. Sanchez-Rodriguez A., Sansegundo E., Tourmente M., Roldan ERS. Effect of High Viscosity on Energy Metabolism and Kinematics of Spermatozoa from Three Mouse Species Incubated under Capacitating Conditions // International Journal of Molecular Sciences. 2022. Vol. 23. № 23. P. 15247 – 15279. doi: 10.3390/ijms232315247
  10. Berger G.K., Smith-Harrison L.I., Sandlow J.I. Sperm agglutination: Prevalence and contributory factors.// Andrologia. 2019. Vol. 51. № 5. P. e98903. Doi.org/ 10.1111/and.13254
  11. Ni Raghallaigh H., Eeles R. Genetic predisposition to prostate cancer: an update // Familial Cancer. 2022. Vol. 21I. № 1. P. 101 – 114. doi: 10.1007/s10689-021-00227-3
  12. Goldberg H., Grievink L.S., Mano R., Ber Y., Ozalbo R., Tuval S., Baniel J., Margel D. Is there a difference in testosterone levels and its regulators in men carrying BRCA mutations? // Oncotarget. 2022. Vol. 10. Is. 8. P. 103843 – 103850. doi: 10.18632/oncotarget.21802
  13. Shah S., Rachmat R., Enyioma S., Ghose A., Revythis A., Boussios S. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations // International Journal of Molecular Sciences. 2021. Vol. 23. № 22. P. 12628 – 12641. doi: 10.3390/ijms222312628

Supplementary files

Supplementary Files
Action
1. JATS XML

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).